Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024 published by Global Data now available at Zursh

San Diego: The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, with little competition from branded therapies. The market landscape is set to undergo substantial growth between 2014 and 2024.

The main drivers of growth will be an increase in the diagnosed HNC population and the launch of multiple premium-priced metastatic therapies, led by the class of immuno-oncology products. Historically, cytotoxic chemotherapies have comprised the bulk of the HNC market. Little competition between targeted therapies currently exists in the HNC market, leaving an area of considerable opportunity for interested new comers.

The recent investment in HNC has seen a significant increase in research activity. The launch of new agents into the market and continued innovation in the developmental pipeline promises to produce a dynamic market over the forecast period.

Key Topics Covered:

  • Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HNC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Companies Mentioned:
  • Advaxis, Inc.
  • Amgen
  • AstraZeneca
  • Azanta A/S
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CEL-SCI
  • Curis Pharmaceutical
  • Eli Lilly
  • F. Hoffman La-Roche
  • GlaxoSmithKline
  • Glycotope
  • Marsala Biotech
  • Merck & Co. (MSD)
  • Merck KGaA
  • Nordic Pharma
  • Oncolytics Biotech
  • Ono Pharmaceuticals
  • Pfizer
  • Pierre Fabre Medicament
  • Taiho Pharmaceutical
Table of Contents

1.1 List of Tables
1.2 List of Figures
2 Introduction
3 Disease Overview
4 Epidemiology
5 Current Treatment Options
6 Unmet Needs Assessment and Opportunity Analysis
7 R&D Strategies
8 Pipeline Assessment
9 Pipeline Valuation Analysis
10 Appendix

Please find more about OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024 at reports.zursh.com

Click on below items to see free updates about the topic covered.

Industry Updates

Click on below items to see free resources and reports about the topic covered.

Free Resources

Contact Information

Simon Sliman
Simon Sliman (write to Simon)
Research Manager
Zursh Inc. www.zursh.com | reports.zursh.com
Email: reports(at)zursh(dot)com
Lloyd Chambers
Lloyd Chambers (write to Lloyd)
Research Manager
Zursh Inc. www.zursh.com | reports.zursh.com
Email: reports(at)zursh(dot)com

Free Research Updates

Get Latest Updates Completely Free When New Research in Your Industry is Released

Free Research Updates

Get Latest Updates Completely Free When New Research in Your Industry is Released

*We Don't Spam